A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Moderna does not publish either its forward or trailing P/E ratios because their values are negative -- meaning that each ...

Good morning. Trump pumps the brakes on auto tariffs. Moderna expects to launch a personalized cancer vaccine in 2027. And ...